Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD)
NCT07850076Phase 2Not yet recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Oct 2026
- Primary completion
- Jun 2030
01
Overview
Phase 2, open-label trial of CTX460 in alpha-1 antitrypsin deficiency (AATD) and emphysema (2 arms), sponsored by CRISPR Therapeutics. Primary endpoints: Safety and Tolerability at 36 months, Recommended Phase 2 Dose at 36 months and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CTX460
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on NCT07850076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850076.